| 1. |
Ribes JA, Vanover-Sams CL, Baker DJ. Zygomycetes in human disease. Clin Microbiol Rev, 2000, 13(2): 236-301.
|
| 2. |
Tissot F, Agrawal S, Pagano L, et al. ECIL-6 guidelines for the treatment of invasive candidiasis, aspergillosis and mucormycosis in leukemia and hematopoietic stem cell transplant patients. Haematologica, 2017, 102(3): 433-444.
|
| 3. |
Paltauf A. Mycosis mucorina. Archiv F Pathol Anat, 1885, 102: 543-564.
|
| 4. |
Hosseini SM, Borghei P. Rhinocerebral mucormycosis: pathways of spread. Eur Arch Otorhinolaryngol, 2005, 262(11): 932-938.
|
| 5. |
Roden MM, Zaoutis TE, Buchanan WL, et al. Epidemiology and outcome of zygomycosis: a review of 929 reported cases. Clin Infect Dis, 2005, 41(5): 634-653.
|
| 6. |
Spellberg B, Edwards J Jr, Ibrahim A. Novel perspectives on mucormycosis: pathophysiology, presentation, and management. Clin Microbiol Rev, 2005, 18(3): 556-569.
|
| 7. |
Skiada A, Lanternier F, Groll AH, et al. Diagnosis and treatment of mucormycosis in patients with hematological malignancies: guidelines from the 3rd European Conference on Infections in Leukemia (ECIL 3). Haematologica, 2013, 98(4): 492-504.
|
| 8. |
Hassan MIA, Voigt K. Pathogenicity patterns of mucormycosis: epidemiology, interaction with immune cells and virulence factors. Med Mycol, 2019, 57(Supplement2): S245-S256.
|
| 9. |
Rüping MJ, Heinz WJ, Kindo AJ, et al. Forty-one recent cases of invasive zygomycosis from a global clinical registry. J Antimicrob Chemother, 2010, 65(2): 296-302.
|
| 10. |
Skiada A, Pagano L, Groll A, et al. Zygomycosis in Europe: analysis of 230 cases accrued by the registry of the European Confederation of Medical Mycology (ECMM) Working Group on Zygomycosis between 2005 and 2007. Clin Microbiol Infect, 2011, 17(12): 1859-1867.
|
| 11. |
DiBartolo MA, Kelley PS. Rhino-orbital-cerebral mucormycosis (ROCM): a comprehensive case review. Aviat Space Environ Med, 2011, 82(9): 913-916.
|
| 12. |
Baldin C, Soliman SSM, Jeon HH, et al. PCR-based approach targeting mucorales-specific gene family for diagnosis of mucormycosis. J Clin Microbiol, 2018, 56(10): e00746-e00818.
|
| 13. |
Shigemura T, Nishina S, Nakazawa H, et al. Early detection of Rhizopus DNA in the serum of a patient with rhino-orbital-cerebral mucormycosis following allogeneic hematopoietic stem cell transplantation. Int J Hematol, 2016, 103(3): 354-355.
|
| 14. |
Cornely OA, Alastruey-Izquierdo A, Arenz D, et al. Global guideline for the diagnosis and management of mucormycosis: an initiative of the European Confederation of Medical Mycology in cooperation with the Mycoses Study Group Education and Research Consortium. Lancet Infect Dis, 2019, 19(12): e405-e421.
|
| 15. |
Reed C, Bryant R, Ibrahim AS, et al. Combination polyene-caspofungin treatment of rhino-orbital-cerebral mucormycosis. Clin Infect Dis, 2008, 47(3): 364-371.
|
| 16. |
Ibrahim AS, Gebremariam T, Fu Y, et al. Combination echinocandin-polyene treatment of murine mucormycosis. Antimicrob Agents Chemother, 2008, 52(4): 1556-1558.
|
| 17. |
Spellberg B, Walsh TJ, Kontoyiannis DP, et al. Recent advances in the management of mucormycosis: from bench to bedside. Clin Infect Dis, 2009, 48(12): 1743-1751.
|
| 18. |
Pagano L, Cornely OA, Busca A, et al. Combined antifungal approach for the treatment of invasive mucormycosis in patients with hematologic diseases: a report from the SEIFEM and FUNGISCOPE registries. Haematologica, 2013, 98(10): e127-e130.
|
| 19. |
Chamilos G, Lewis RE, Kontoyiannis DP. Delaying amphotericin B-based frontline therapy significantly increases mortality among patients with hematologic malignancy who have zygomycosis. Clin Infect Dis, 2008, 47(4): 503-509.
|
| 20. |
Lanternier F, Poiree S, Elie C, et al. Prospective pilot study of high-dose (10 mg/kg/day) liposomal amphotericin B (L-AMB) for the initial treatment of mucormycosis. J Antimicrob Chemother, 2015, 70(11): 3116-3123.
|
